New drug SHR-2106 tested in healthy volunteers – no cure yet
NCT ID NCT05948059
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new drug, SHR-2106, in 52 healthy adults to see if it is safe and how the body processes it. Participants received a single dose either through a vein or under the skin. The goal was not to treat any disease, but to gather important safety information for future research in kidney transplant patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The third xiangya hospital of central south univercity
Changsha, Hunan, 410013, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI may spot hidden kidney transplant rejection
- A drug given to organ donors may help kidneys work faster after transplant
- Which diuretic protects a new kidney best? a Head-to-Head trial puts furosemide and mannitol to the test
- Blood test clues could make antifungal dosing safer for transplant patients
- New Two-Step therapy aims to stop chronic kidney transplant rejection
- Smartphone app and booklet could help kidney transplant patients stick to medications